RFS
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Georgina V Long, Charlie Garnett-Benson, Sonia Dolfi, Paolo A Ascierto, Jun Guo, Ahmad A Tarhini, Sunandana Chandra, Eva Muñoz-Couselo, Michele Del Vecchio, Andreia Cristina de Melo, Margaret Callahan, Helen Gogas, Reinhard Dummer, Dirk Schadendorf, Peter Koelblinger, Gaelle Quereux, Ioannis Thomas, Jia Xin Yu, Andrew Fisher, Bonnie Wang, Patrick Djidel, Armand Chouzy, Mark Semaan, Bohang Chen, Alicia M Y Cheong, Hussein A Tawbi
Nat Med 31(12) 4301-4309
Based on RELATIVITY-047, nivolumab plus relatlimab is approved for advanced melanoma. Here, to address a current unmet need for more efficacious adjuvant regimens for completely resected melanoma, the phase 3, double-blind RELATIVITY-098 trial compared adjuvant nivolumab plus relatlimab to nivolumab after complete resection of stage III/IV melanoma. Patients were randomized 1:1 to receive nivolumab 480 mg plus relatlimab 160 mg (n = 547) or nivolumab 480 mg (n = 546) intravenously every 4 weeks for ≤1 year; safety populations totaled 543 and 545 patients, respectively. The primary endpoint was recurrence-free survival (RFS), and the key secondary was overall survival; translational endpoints were exploratory. There was no difference in RFS for nivolumab plus relatlimab versus nivolumab (hazard ratio = 1.01; 95% confidence interval: 0.83-1.22; P = 0.928); therefore, overall survival was not tested. Translational data across trials showed lower circulating LAG-3+ T cells in the adjuvant setting (RELATIVITY-098) versus advanced melanoma (RELATIVITY-047), where LAG-3+ T cells were enriched in tumor versus blood. The absence of macroscopic tumor and reduced peripheral LAG-3+ T cells may explain the lack of added benefit of nivolumab plus relatlimab over nivolumab in resected versus metastatic melanoma. ClinicalTrials.gov identifier: NCT05002569 .
2 个 Figure · 3 个 KM 面板
Fig. 2. RFS and DMFS. a , Kaplan–Meier estimates of RFS defined as the time between randomization and the first date of documented recurrence (local, regional or distant recurrence or new primary melanomas (excluding in situ)) or death due to any cause in all randomized patients. b , DMFS defined as the time between randomization and first distant metastasis or death due to any cause in a subset of intention-to-treat patients, defined as those with resected stage III−IVA−IVB melanoma (those without presence of baseline metastasis prior to surgical resection—that is, stage III cutaneous and stage IVA−IVB mucosal melanoma). RFS statistical analysis was two-sided log-rank test, with no multiple comparisons. Symbols (circles) indicate censored data. Dashed lines indicate landmark analyses. CI, confidence interval; HR, hazard ratio; mDMFS, median DMFS; mRFS, median RFS; mo, months; NIVO, nivolumab; NR, not reached; RELA, relatlimab.
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel B
Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 1. OS. Kaplan–Meier estimates of OS defined as the time between randomization and death. Symbols (circles) indicate censored data. Dashed lines indicate landmark analyses. mOS, median OS; NIVO, nivolumab; NR, not reached; RELA, relatlimab.
Extended Data Fig. 1 · Panel OS
Panel OS 是同一 Extended Data Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。